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Abstract
Background: The sensitivity of chronic lymphocytic leukemia (CLL) cells to current treatments, both in vitro and
in vivo, relies on their ability to activate apoptotic death. CLL cells resistant to DNA damage-induced apoptosis
display deregulation of a specific set of genes.
Methods: Microarray hybridization (Human GeneChip, Affymetrix), immunofluorescent in situ labeling coupled with
video-microscopy recording/analyses, chromatin-immunoprecipitation (ChIP), polymerase chain reactions (PCR), real-
time quantitative PCR (RT-QPCR) and bisulfite genome sequencing were the main methods applied. Statistical
analyses were performed by applying GCRMA and SAM analysis (microarray data) and Student’s t-test or Mann &
Whitney’s U-test.
Results: Herein we show that, remarkably, in a resistant male CLL cells the vast majority of genes were down-
regulated compared with sensitive cells, whereas this was not the case in cells derived from females. This gene
down-regulation was found to be associated with an overall gain of heterochromatin as evidenced by
immunofluorescent labeling of heterochromatin protein 1a (HP-1), trimethylated histone 3 lysine 9 (3metH3K9),
and 5-methylcytidine (5metC). Notably, 17 genes were found to be commonly deregulated in resistant male and
female cell samples. Among these, RELB was identified as a discriminatory candidate gene repressed in the male
and upregulated in the female resistant cells.
Conclusion: The molecular defects in the silencing of RELB involve an increase in H3K9- but not CpG-island
methylation in the promoter regions. Increase in acetyl-H3 in resistant female but not male CLL samples as well as
a decrease of total cellular level of RelB after an inhibition of histone deacetylase (HDAC) by trichostatin A (TSA),
further emphasize the role of epigenetic modifications which could discriminate two CLL subsets. Together, these
results highlighted the epigenetic RELB silencing as a new marker of the progressive disease in males.
Background
The CLL is currently incurable and is associated with a
high incidence of morbidity and mortality in the elderly.
Men are more frequently affected than women (0.6/0.4),
develop the disease at a younger age [1,2] and often
exhibit a more aggressive form of this disease [3].
Consistent with these observations, CLL cells in men
more commonly display no mutations in genes of the
immunoglobulin variable heavy chain region (IgVH),
which is a known indicator of a poor prognosis [4].
When gene expression profiles were previously categor-
ized according to the status of IgVH genes, males segre-
gated into a distinct subgroup [5]. The current front
line therapies for CLL include fludarabine (nucleoside
analogue) or chlorambucil (alkylating agent) both of
which should induce apoptosis through DNA damage.
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response similar to that induced by the in vitro exposure
of cells to ionizing irradiation [6] suggesting the com-
mon mechanisms achievable by these two treatments.
We previously identified the altered expression of a
specific subset of genes in leukemic cells that displayed
resistance to DNA damage-induced apoptosis, and
defined a clinically distinct, aggressive form of CLL [7].
Other groups have identified genes associated with cer-
tain CLL subtypes defined by patient survival and
disease staging [8], IgVH mutation status [9,10] or
CD38-expression [11]. CLL has also been associated
with global DNA hypomethylation and a hypermethyla-
tion of GC-rich promoter regions [12,13], two aberrant
epigenetic events that cause chromatin structural
changes and subsequent de-regulated gene expressions
[14,15]. DNA methylation of CpG islands in the promo-
ter regions of specific cancer-relevant genes, which often
occur concomitantly with covalent modifications of his-
tones and/or with the appearance of their variants,
establishes a direct epigenetic basis for cell transforma-
tion. Thus, cancer cells display genetic lesions (muta-
tions, deletions and translocations) and significant
epigenetic changes that convey heritable gene expression
profiles critical for tumorigenesis [16]. In this regard
epigenetic control of gene expression has been shown in
both sporadic and familial CLL [17].
Based upon the sex-related differences in the occur-
rence of CLL, the clinical outcomes of this, and the abil-
ity to unambiguously distinguish progressive from
indolent cases by evaluating the susceptibility to apopto-
sis after DNA damage in vitro, the aim of our present
study was to screen for new genes that could discrimi-
nate between CLL types classified using these para-
meters. We used oligonucleotide microarrays to analyze
resistant and sensitive CLLs from patients and healthy
donors and further validated these results by RT-QPCR.
Intriguingly, when compared with sensitive samples,
male resistant samples revealed a generalized down-reg-
ulation (98%) of gene expression not seen in the corre-
sponding female samples. This characteristic of resistant
male CLLs was also associated with a more compact
chromatin and more widespread heterochromatic fea-
tures than in female samples. Furthermore, male and
female CLL cell samples shared 17 genes which could
distinguish between resistant and sensitive cases. Among
these genes, RELB was found to be down-regulated in
resistant male but up-regulated in female CLL samples.
We have now established that the reduced expression of
RELB in male samples is the result of epigenetic silen-
cing through increased levels of 3metH3K9 in three pro-
moter regions of this gene: region of 58 bp, 121 bp and
74 bp (333-391 bp, 529-650 bp and 1117-1191 bp from
transcription initiation site respectively). In parallel,
up-regulation of RELB in resistant female CLL samples
was documented by an increase of acetyl-H3, hallmark
of an activated gene expression. Taken together, these
results strongly suggest that RELB silencing may be
involved in the development of resistant subtypes of
CLL in males.
Methods
Patients and clinical characteristics
Twenty-five CLL samples were selected from our cohort
according to their sensitivity to apoptosis. Blood from
leukemic (CLL) and healthy donors was collected in
heparin-coated tubes or blood-packs after informed con-
sent. B lymphocytes were isolated as previously
d e s c r i b e d[ 7 ]w i t hap u r i t yo f8 6±3 %a n d9 5±3 %f o r
normal and leukemic B-cells, respectively. The mean
percentage of apoptotic cells was determined 24 hours
a f t e re x p o s u r et o1 0G y(
137Cs source). For sensitive
samples, the level of apoptosis increased from 8.7 ±
1.5% (spontaneous apoptosis) to 73.3 ± 26.3% after irra-
diation, whereas for resistant samples the apoptosis level
of irradiated cells remained unchanged (6.3 ± 3.1% com-
pared to 7.3 ± 3.5% spontaneous apoptotic cells). All
CLL patients had lymphocytosis ranging from 5 × 10
9/L
to 20 × 10
9/L and had not been treated for at least 3
months prior to blood sampling. The clinical character-
istics of our CLL patients are summarized in Table 1.
The 22 age-matched healthy individuals included in this
study were free of acute or chronic disease.
This study was approved by the Pitié-Salpêtrière
Ethics Committee and the CEA Review Board.
RNA extraction, DNA arrays and analysis
Total RNA was extracted using RNA-Now (Biogentex,
Seabrok, TX) according to the supplier’si n s t r u c t i o n s .
RNA quality was checked using a Bioanalyzer 2100
(Agilent technologies, Santa Clara, CA). Two series of
analyses were performed that included male and female
cell samples. Each series comprised RNAs obtained
from three resistant and three sensitive CLL samples,
and three healthy donors. Three pools were prepared by
mixing equal quantities of each set of samples. Gene
expression profiling used the Human U133 Set A-B
GeneChip for CLL male samples, and the Human U133
2.0 Plus GeneChip (Affymetrix, Santa Cruz, CA) for all
other specimens. GeneChip array design and detailed
protocols for microarray hybridization are available from
Affymetrix. The fluorescence intensity was measured for
each microarray and results were normalized via the
robust GCRMA procedure (multiple-array average with
adjustment for GC content of probes and quantile nor-
malization) using R software to compare the different
GeneChips [18]. According to standardized guidelines
[19] significantly up- or down-regulated genes were
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ian false-discovery rate of 1% and a 2-fold change. To
avoid any bias in comparison of gene expression
between males and females, only genes represented on
t h eU 1 3 3s e tA - Ba r r a yh a v eb e e nk e p ta f t e rG C R M A
procedure and before SAM analysis.
Validation of microarray data by real-time quantitative
RT-QPCR
The expression of 10 randomly selected genes signifi-
cantly related to CLL, apoptosis resistance and/or gender
status was analyzed in additional samples from 12 CLL
patients and 6 healthy donors. The genes included CCL3,
CD86, CNTNAP2, CTBP1, LSM3, MVK, RELB, SC4MOL,
TMEM33 and UBE2D1 and were analyzed by real-time
quantitative RT-QPCR using an ABI PRISM 7000
Sequence Detection System with Taqman probes and the
manufacturer’ conditions (Applied Biosystems). Briefly,
1 μg of total RNA was incubated at 70°C for 3 min in the
presence of anchored oligo dT primers (ABgene, Epsom,
UK), and then reverse transcribed at 42°C for 1 hour in
the presence of 250 U M-MuLV reverse transcriptase
(ABgene). Quantitative RT-QPCR was performed with
Taqman technology using 5 μl of diluted cDNA (1:50),
1.25 μl of the gene expression array and 12.5 μl of Abso-
lute QPCR ROX mix (ABgene) in a final volume of 25 μl.
Amplification included an initial denaturation at 95°C for
10 min, followed by 45 cycles at 95°C for 15 s and 60°C
for 1 min. Results were normalized to the b-actin gene
(ACT) which was simultaneously amplified.
In situ immunofluorescent heterochromatin labeling
The B-cells used for immunofluorescent labeling
of HP1a, 3metH3K9 and 5metC were prepared as
Table 1 Clinical characteristics and outcomes of CLL patients
Patient’s
ID
Sex Age
(years)
Binet’s
stage
FISH Aberrations Treatment Matutes sCD23
PVT
Apoptosis in
vitro
B118R Male 89 A del(13q14) biallelic; del(11q22)monoallelic yes 5 160 Resistant
G151R Male 56 A del(13q14)biallelic yes 5 ND Resistant
E147R Male 70 A del(13q14)biallelic; del(17p13)monoallelic yes 4 ND Resistant
B138R Male 65 A del(13q14)monoallelic yes 5 ND Resistant
RM1 Male 81 A del(13q14)biallelic; del(17p13)monoallelic yes 5 105 Resistant
RM2 Male 77 A del(13q14)biallelic yes 5 400 Resistant
RM3 Male 56 A del(13q14)monoallelic yes 4 102 Resistant
RF1 Female 74 A del(13q14)biallelic; del(17p13)monoallelic yes 5 443 Resistant
RF2 Female 67 A del(13q14)monoallelic; del(17p13)
monoallelic
yes 5 72 Resistant
RF3 Female 56 A del(13q14)biallelic; del(17p13)monoallelic no 5 ND Resistant
U231R Female 76 A del(13q14)monoallelic yes 5 ND Resistant
G244S Female 63 A del(13q14)monoallelic; del(17p13)
monoallelic
no 5 ND Sensitive
B229S Female 78 A del(13q14)monoallelic no 5 ND Sensitive
S240S Female 67 A no no 4 ND Sensitive
SF1 Female 80 A ND no 4 70 Sensitive
SF2 Female 62 A ND no 4 28 Sensitive
SF3 Female 84 A ND no 5 97 Sensitive
SM1 Male 82 A ND no 4 52 Sensitive
SM2 Male 65 A no no 5 high Sensitive
SM3 Male 74 A del(13q14)monoallelic no 4 low Sensitive
L130S Male 77 A del(13q14)monoallelic no 4 ND Sensitive
S152S Male 77 A ND no 4 458 Sensitive
B130S Male 77 A del(13q14)monoallelic yes 4 93 Sensitive
B118S Male 89 A del(11q22) monoallelic yes 4 160 Sensitive
M124S Male 83 A ND no 5 ND Sensitive
Apoptosis score was established 24 h after cell exposure to 10 Gy of g-rays. Patients were considered sensitive (S) when the number of apoptotic cells was at
least twofold higher in irradiated cells than in non-irradiated at 24 h of cell culture, or as resistant (R) when no difference was observed between irradiated and
non-irradiated cells. Patients RM2 and B118S/R shifted from S to R status. Matutes scoring system was established to distinguish CLL from other
lymphoproliferative disorders. This score is based on the immunophenotypic analysis of five markers: CD5
+, CD23
+, FMC7
- and CD79b
-, weak expression of
monotypic  or l light chain. A value of 1 is assigned to a given marker with a level typical of CLL, and a total Matutes score at 4 or 5 indicates diagnosis of
typical CLL. ND, not determined. Chromosomal aberrations were established by FISH using LSI ATM/LSI p53 and LSI D13S319/LSI 13q34/CEP12 probe sets
(Abbott, France) which are complementary to 11q22.3, 17p13.1, 13q14.3, 13q34 and 12p11.1-q11 genome regions, respectively. To be taken into account, the
aberration should be present in at least 5% of nuclei.
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HP1a, 3metH3K9 (Upstate Biotechnology, Lake Placid,
NY) or 5metC (Abcam, Cambridge, UK) (1:100) antibo-
dies overnight at 4°C, followed by incubation for 1 h
with a Cy3-conjugated goat anti-rabbit secondary anti-
body (Jackson ImmunoResearch, West Grove, PA) to
visualize 3metH3K9, and FITC-conjugated rabbit anti-
mouse IgG (Jackson ImmunoResearch, West Grove, PA)
to visualize HP1a-associated chromatin or DNA methy-
lation. After staining with DAPI, slides were mounted
with p-phenylenediamine (Sigma Aldrich, Steinheim,
Germany). Quantification of 3metH3K9 and HP1a foci/
nucleus and measurements of 5metC areas were per-
formed on projections of a Z-stack of 40 images using a
100X objective of an Olympus IX81 microscope and a
Coolsnap HQ camera (Princeton Instruments). Image
analysis used MetaMorph software (Ver 6.32; Molecular
Devices). Quantification of H3K9, HP1 or 5metC label-
ing was performed for 3D objects in a stack with a mini-
mum voxel number of 15. The differences of total
labeling between samples (obtained by summing the
volumes of 3D objects) reflected the differences in the
distribution patterns or labeling levels. Differences in
mean areas were considered significant for a p-value
< 0.01 by the Student t-test.
Immunoblotting analysis
Total proteins were extracted from 5 × 10
6 B cells from
R M( n=1 0 ) ,S M( n=7 ) ,R F( n=6 )a n dS F( n=9 )
subsets as described previously [22]. Proteins (10 μg)
were separated by SDS-PAGE and transferred onto an
Immobilon transfer membrane (Millipore-France).
Membranes were incubated in TBS with 5% non-fat
milk containing antibodies against RelB (Cell Signaling
Technology, Danvers, MA) or actin (Thermo Scientific,
France). Following staining with secondary antibodies,
the proteins were detected with Supersignal West Pico
chemiluminescent substrate (Pierce, Rockford, IL).
Image Quant software (Amersham France) was used to
quantify signal intensities and RelB levels were normal-
ized with b-actin.
Bisulfite genomic sequencing
Genomic DNA (500 ng) from CLL samples and normal
controls was converted with bisulfite using the EZ DNA
methylation kit (Zymo Research Corp, CA) according to
the manufacturer’s instructions. The sequence extending
from the -259 bp region of the promoter to the +169 bp
of exon 1 was amplified using 2 μl of bisulfite DNA, 2.5
units of AmpliTaq Gold polymerase (Applied Biosys-
tems), and RELB forward (5’-GTGATGGTTTTAAG-
TAGG-3’) and reverse (5’-CCAAAACTAACCCAAAC)
primers. Amplification conditions included an initial
denaturation at 95°C for 10 min, followed by 30 cycles
at 95°C for 30 s, 55°C for 30 s, and 72°C for 45 s. For
bisulfite sequencing, the PCR products were purified
from a 1% agarose gel using the Qiagen Gel Extraction
kit (Qiagen France) and subcloned using the p-GEMT
Easy Vector system (Promeg a ,M a d i s o n ,W I ) .F i v e
clones per sample (two patients per each CLL subset)
were then sequenced.
Chromatin immunoprecipitation (ChIP) and Q-PCR of anti-
3metH3K9 and anti-acetyl-H3 immunopurified chromatin
Preliminary assays allowed us to determine the immu-
noprecipitation conditions to ensure that the amount of
antibody and percentage of cross-linking agent were not
limiting in the ChIP yields. Freshly isolated B lympho-
cytes (4 × 10
7) from RM (n = 6), SM (n = 6), RF (n = 6)
a n dS F( n=6 )w e r ec r o s s - l i n k e df o r1 0m i na t3 7 ° Ci n
0.5% formaldehyde. Fixed cells were washed twice with
ice-cold PBS and lysed in 400 μl of ChIP lysis buffer for
10 min (Tris 50 mM pH 8, EDTA 10 mM, SDS 1%).
Chromatin fragments between 250 bp and 3000 bp were
then produced by sonication with a Branson sonifier
450. Five μg of 3metH3K9 or acH3K9/acH3K14 antibo-
dies (#07-442 and #06-599, respectively, Upstate Bio-
technology, CA, USA), were used to precipitate 1.5 μg
of fragmented chromatin measured using Quant it Pico-
Green dsDNA Reagent (Molecular Probes, Invitrogen,
France). Immunoprecipitations were carried out in buf-
fer containing 0,1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl (pH 8,0), 150 mM NaCl and a
protease inhibitor cocktail at 4°C overnight. A negative
control without antibody was run simultaneously with
the samples. Immunocomplexes were collected by
adsorption to protein A sepharose CL-4B (Amersham)
beads blocked in 0.5% BSA according to the manufac-
turer’s protocol. Washing and elution of immunocom-
plexes were carried out as described elsewhere [23].
Cross-linking was reversed for 5 h at 65°C and samples
were then treated with proteinase K. Immunoprecipi-
tated DNA was extracted with phenol-chloroform-
isoamyl alcohol. Three regions of the RELB promoter
were assessed for the presence of trimethylated histone
H3 using Q-PCR. The location of promoter RELB and
primer sequences are indicated in Figure 1 and Figure 2.
Amplification was performed using 12.5 μl of absolute
QPCR SYBR Green ROX mix (Thermo Scientific
France), 10 μM of each primer and 100 ng of DNA in a
final volume of 25 μl. Amplification conditions included
an initial denaturation at 95°C for 15 min, followed by
30 cycles at 95°C for 15 s, 56.2°C for 30 s, and 72°C for
30 s. Serial dilutions of control DNA ranging from 200
to 0.02 ng were used for quantification of the signal.
The levels of 3metH3K9 and acetyl-H3 in the three pro-
moter regions of RELB were expressed as the percentage
of the input chromatin fraction defined by the following
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antibody-chromatin fraction without antibody)/input
chromatin fraction.
Results
The gene expression signatures for apoptosis resistance
in CLL differ between males and females
Comparisons of gene expression profiles between resistant
and sensitive CLL subsets were assessed separately for
males and females. In males, the vast majority of the genes
had lower expression levels in resistant compared with
sensitive CLL samples (463 out of 472 genes, 98%) (Addi-
tional file 1, Figure S1a). In contrast, over- and under-
expressed genes in females were equally represented in
resistant (475 out of 803 genes, 59%) and sensitive samples
(328 out of 803 genes, 41%) (Additional file 1, Figure S1b).
Only 17 genes that distinguished resistant from sensitive
CLL were found to be common between male and female
patients. Remarkably, for three of these genes (RELB,
CTBP1,a n dTMEM33), the relative expression levels
reflected by the R vs. S ratios were opposite between male
and female patients (Table 2). Moreover, as evidenced
from the comparative analysis of transcriptome profiles
from healthy male and female control samples (Additional
file 1, Figure S1c), the set of 419 significant differentially
expressed genes included only one of the above 17 genes
(CACNA1A). Additional file 1 Table S1 shows that a
majority of NFB target genes appeared as down-regulated
in resistant males’ while an upregulation was observed in
females’ samples. Taken together, these data suggest that
the gene expression signature for resistance is dependent
upon the sex of the patient. To validate these microarray
data, we further performed RT-QPCR for 10 randomly
selected genes in an additional 12 CLL patients and 6
healthy donors (Additional file 1, Figure S2) including the
RELB, TMEM33 and CTBP1 genes.
Figure 1 Epigenetic modifications of histone H3 and RelB expression: histone H3K9 trimethylation in the RELB promoter (using ChIP
and Q-PCR). Chromatin was immunopurified by anti-3meH3K9 immunoprecipitation (ChIP) and the levels of 3metH3K9 in the three promoter
regions of RELB were established by Q-PCR SYBR Green. These levels were expressed as the percentage of the input chromatin fraction defined
in Material and Method section. Ns: non significant. The sequences of the primers used for amplifying the three indicated RELB promoter regions
are: 74 bp amplicon: forward primer 5’ CTGGTGATAGGGATGAGC 3’ and reverse primer 5’ CGAATGGCAGCAGTGTA 3’; 121 bp amplicon: forward
primer 5’ GGGTTACAACAACGCACAA 3’ and reverse primer 5’ CCTCCAAGGTCTCGCTAC 3’; 58 bp amplicon: forward primer 5’
TGCTCAATGGGTAAGGC 3’ and reverse primer 5’ TGCTCTGGACGAGACAAC3’.
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from healthy individuals, and also resistant from sensitive
CLL cell types
We addressed the question of whether epigenetic mar-
kers for chromatin organization may underlie the
observed differences in gene expression according to the
resistance or sensitivity status and sex of the patient. A
preferential perinuclear localization of 5metC labeling
was observed in cells from healthy donors compared
with a more diffuse intra-nuclear pattern in CLL cells,
irrespective of patient status or sex (Figure 3). This dif-
ference may be of particular interest since perinuclear
region contains actively transcribed genes whose expres-
sion might be controlled by 5metC in normal B cells
but much less in CLL cells. The level of 5metC labeling
was significantly lower in CLL samples than in healthy
tissues (n = 81 vs. n = 33 spots; p < 0.001), consistent
with the previously described hypomethylation of CLL
cells [12]. In addition, resistant individuals showed a
higher level of DNA methylation than sensitive cases
(n = 42 vs. n = 37 spots; p < 0.01) with stronger 5metC
l a b e l i n gi nm a l e st h a ni nf e m a l e s( n=2 3v s .n=1 9
spots; p < 0.015). This was not due to differences
between healthy males and females (n = 18 vs. n = 15
spots; p = 0.07). No differences in the distributions were
observed by sex in sensitive individuals.
Immunofluorescence labeling with HP1a and
3metH3K9, which are known to be associated with het-
erochromatin formation and the transcriptional repres-
sive state, was also assessed to evaluate structural and
functional chromatin organization. Localization of the
HP1a isoform within the nucleus of interphase B-cells
revealed a different chromatin organization between
CLL and healthy samples (Figure 3). The chromatin
appeared to be more condensed in resistant cells com-
pared with sensitive cells or control cells (Figure 3).
Although the 3metH3K9 or HP1a distributions were
similar between healthy male and female cells, they
Figure 2 Epigenetic modifications of histone H3 and RelB expression: histone H3K9-K14 acetylation in the RELB promoter (using ChIP
and Q-PCR). Chromatin was immunopurified by anti-3meH3K9 or anti-acetyl-H3 immunoprecipitations (ChIP) and the levels of 3metH3K9 and
acetyl-H3 in the three promoter regions of RELB were established by Q-PCR SYBR Green. These levels were expressed as the percentage of the
input chromatin fraction defined in Method section. Ns: non significant; *for resistant male samples the values for the level of acetyl-H3 were too
low to allow the calculation of the percentages. The sequences of the primers used for amplifying the three indicated RELB promoter regions
were the same as described for histone H3K9 trimethylation (Figure 1).
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according to sex (Figure 4 and Figure 5, respectively).
For all but the sensitive male subset, the distributions of
HP1a and 3metH3K9 in CLL differed from the healthy
counterparts. These data provide evidence of striking
differences in the chromatin organization between CLL
subsets with a notably more condensed chromatin in
resistant CLL in males.
Increased 3methyl-H3K9 in the promoter region of the
RELB gene occurs in resistant male but not resistant
female CLL and inversely, increased level of acetyl-H3
occurs in resistant female but not resistant male CLL
Given the differences in the chromatin organization
between CLL subsets, we next focused on searching for
epigenetic changes at the specific RELB locus as this gene
was identified as under-expressed in resistant vs. sensitive
cells in males and over-expressed in resistant cells in
females. Consistent with the transcript levels, we found
that the levels of the RelB protein were significantly
decreased in resistant male CLL cells when compared
with sensitive cells. In contrast, the RelB levels were
increased in all female CLL subsets (Figure 6). The DNA
methylation status of 58 CpG sites located within the
RELB promoter and exon 1 of this gene was examined
using bisulfite genomic sequencing. DNA from healthy
donors and CLL patient B cells were treated with sodium
bisulfite allowing conversion of unmethylated cytosine to
uracil and then used for PCR amplification of a 400 bp
sequence. Following cloning of the PCR products, five
clones per DNA sample were sequenced.
A ss h o w ni nF i g u r e7 ,n od i f f e r e n c e si nt h eD N A
methylation of RELB between the different CLL subsets
were detectable, at least for this 5’ region and the first
exon. The 3metH3K9 histone modifications that are
known to be involved in gene silencing were analyzed
by chromatin immunoprecipitation. The total DNAs
that cross-linked to 3metH3K9 were then used in RT-
QPCR reactions with oligonucleotide primers specific
for three regions of the RELB promoter (Figure 1) cov-
ering a 1 kb 5’ upstream region from the transcriptional
initiation site. Two of these promoter regions contain
the consensus DNA binding site for the STAT3 or
PAX5 transcription factors (Figure 1 and additional file,
Table S2). The results showed a significant increase in
the 3metH3K9 levels in resistant male but not in female
CLL samples (Figure 1). In parallel, the level of acetyl-
H3 (antibody recognizes acetylated lysine K9 and K14),
used as a positive epigenetic marker associated with
increased gene expression, showed low level in male and
high level in resistant female samples. Moreover, in
female CLL, the increase of acetyl-H3 level in two RELB
promoter regions (74 bp and 121 bp) is significant when
resistant samples were compared to sensitive (Figure 2).
To further explore if RELB expression may be under
an epigenetic control we have sought whether it may be
Table 2 Significantly up- and down-regulated genes that discriminate resistant (R) from sensitive (S) CLL patients and
that are common to males (M) and females (F)
Gene name* Gene
Symbol
Chromosome
Location
Fold change
RM vs. SM
Fold change
RF vs. SF
trafficking protein, kinesin binding 2 TRAK2 2q33 0.054 0.379
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CACNA1A 19p13.2-p13.1 0.116 0.135
contactin associated protein-like 2 CNTNAP2 7q35-q36 0.003 0.060
C-terminal binding protein 1 CTBP1 4p16 0.290 2.344
discs, large (Drosophila) homolog-associated protein 4 DLGAP4 20q11.23 0.164 0.389
DNA polymerase-transactivated protein 6 DNAPTP6 2q33.1 0.199 0.177
developmentally regulated GTP binding protein 2 DRG2 17p11.2 0.320 0.442
G protein pathway suppressor 2 GPS2 17p13 0.430 0.425
HOM-TES-103 tumor antigen-like HOM-
TES-103
12p13.3 0.303 0.446
integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha
polypeptide)
ITGAE 17p13 0.450 0.434
phosphoribosylformylglycinamidine synthase (FGAR amidotransferase) PFAS 17p13.1 0.320 0.457
pleckstrin homology domain containing, family B (evectins) member 1 PLEKHB1 11q13.5-q14.1 0.203 0.484
RNA binding motif, single stranded interacting protein 1 RBMS1 2q24.2 0.036 0.352
v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa
light polypeptide gene enhancer in B-cells 3
RELB 19q13.31-
q13.32
0.245 3.033
transmembrane protein 33 TMEM33 4p13 0.203 2.013
vesicle-associated membrane protein1, synaptobrevin1 VAMP1 12p 0.287 0.395
vanin 2 VNN2 6q23-q24 0.434 0.424
*Genes listed were identified as being differentially expressed after direct comparisons of gene expression profiles between resistant and sensitive CLL samples
for males and females. FC, fold change.
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Page 7 of 15modified by HDAC inhibition. For this purpose we have
pretreated primary CD19
+ B cells from healthy donor,
CLL cells and Ramos B cell line with a general HDAC
inhibitor trichostatin A (TSA) at 200 nM for 16 hrs and
then performed Western blot analysis of total cellular
level of RelB. As shown (Figure 8), HDAC inhibition
resulted in a decreased level of RelB in all B cell types
tested.
Discussion
The most relevant contribution to date of microarray
technology to the biology of CLL is certainly the identifi-
cation of a homogeneous phenotype related to memory B
cells [9] and its classification as a distinct type of B lym-
phoma [24]. In particular, for a given CLL subset defined
by disease aggressiveness, this method may provide new
insights into mechanisms that have yet to be revealed. In
addition to transcriptional changes defined by the micro-
array approach, it has become evident that epigenetic
alterations that determine structural and functional chro-
matin organization should be integrated into these types
of studies. Indeed, molecular profiling in CLL has allowed
the identification of new genes for which the expression
is dependent on CpG island methylation [13]. The down-
regulation of the death-associated protein kinase 1
(DAPK1) gene in CLL indicates that both genetic and
epigenetic factors may define both the sporadic and
inherited forms of this disease [17].
In our current study, we employed a microarray meth-
odology to search for potential candidate genes that may
discriminate aggressive cases of CLL according to the
sex of the patient. In our previous studies, we reported
that in aggressive forms of CLL, the cells display
partially defined mechanisms enabling them to avoid
Figure 3 Distribution of HP1a, 3metH3K9 proteins and 5metC in human CLL cells. Representative images are shown for the localization of
HP1a (a-x). All cells were stained with DAPI (blue) (a,e,i,m,q,u). Cells were stained with a polyclonal antibody against 3metH3K9 (red) (b,f,j,n,r,v) a
marker of inactive chromatin and antibody against HP1a (green) (c,g,k,o,s,w) a marker of heterochromatin. Merged images show the co-
localization of these two proteins. Labeling with a 5metC antibody (green) (1-6) revealed a global hypomethylation state and a more diffuse
pattern in CLL cells (1-4) vs. control cells (5-6). Scale bar, 2 μm.
Marteau et al. BMC Medical Genomics 2010, 3:53
http://www.biomedcentral.com/1755-8794/3/53
Page 8 of 15apoptotic death following DNA damage [7,22,25]. Thus,
comparing resistant and sensitive CLL samples accord-
ing to patient sex, the gene expression profile of resis-
tant cells in male patients was found unexpectedly to
differ from females. This suggests that analyses based on
cellular susceptibility to DNA damage-induced apoptosis
combined with patient sex may reveal a new sub-class
of CLL that has previously been unknown.
Figure 4 Comparison of 3metH3K9 levels between resistant and sensitive CLL and healthy cell samples (A) and between each
subgroup according to the gender (B). For each type of labeling 40 cells for each subgroup were analyzed. 3metH3K9 was at significantly
greater level in CLL than in healthy controls, and up-regulated in resistant compared with sensitive CLL patients (arbitrary units). Differences in
the mean areas were considered significant for a p-value < 0.01 by Student’s t-test (A) or U-test (B). Comparisons between each CLL phenotype
(n = 20) and their control counterparts are given at the bottom of the figure (i.e. RM vs. HM; RF vs. HF; SM vs. HM and SF vs. HF). Results are
presented using box-plots with medians (lines inside boxes), 25th and 75th percentiles (limits of boxes), and the 10th and 90th percentiles
(whiskers). Outliers are also indicated. RM, resistant male; RF, resistant female; SH, sensitive male; SF, sensitive female; HM, healthy male; HF,
healthy female. ****, p < 0.0001; ***, p < 0.001 < p; **, p < 0.01; *, p < 0.05; ns, not significant.
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Page 9 of 15CLL cells that are resistant to DNA damage-induced
apoptosis may harbor mutated as well as wild type IgVH
genes, mutated or wild-type TP53, and any different
(probably multiple) types of chromosomal aberrations.
In contrast, sensitive cells contain wild-type TP53 only
and any (but probably a unique) type of chromosomal
aberration [25] (Table 1). These biological markers have
previously been used as criteria to select and to class
CLL samples for microarray analyses but are not neces-
sarily linked to the susceptibility of CLL cells to DNA
damage-induced apoptosis. We thus evaluated whether
this last type of CLL classification may be useful in
Figure 5 Comparison of HP1a levels between resistant and sensitive CLL and healthy cell samples (A) and between each subgroup
according to the gender (B). For each type of labeling 40 cells for each subgroup were analyzed. HP1a was at significantly greater level in
CLL than in healthy controls, and up-regulated in resistant compared with sensitive CLL patients (arbitrary units). Statistical analyses and results
presentation were the same as described for Figure 2.
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Page 10 of 15identifying new molecular markers which have not been
elucidated using other characteristics of this disease.
Remarkably, when male and female CLL samples were
compared in terms of their ability to undergo apoptosis,
all but 2% of the genes in the male samples were under-
expressed in resistant compared with sensitive CLL types.
In contrast, 41% of the genes were under-expressed in
resistant female CLL samples (Additional file 1, Figure S1).
The significant difference between resistant male and
female CLL is emphasized by the very low number of
genes in common, (17 in total) between these subsets
(Table 2). Thus, it was striking that in the resistant male
subset, 98% of the genes were down-regulated. Based on
this observation, we addressed whether global chromatin
Figure 6 Western blot analysis of RelB in CLL patients. The expression of RelB is higher in resistant CLLs in females (RF) (n = 6, 21.2 ± 15.5)
than in resistant CLL in males (RM) (4.2 ± 4.8, n = 10), U test p = 0.0048; higher also in resistant females (RF) (n = 6, 21.2 ± 15.5) vs. sensitive
females (SF) (6.2 ± 5.5, n = 7), U test p = 0.0184; higher in sensitive males (SM) (12.2 ± 8.0, n = 7) compared with resistant males (RM) (4.2 ± 4.8,
n = 10), U test p = 0.0147; but no different between sensitive males (SM, n = 7) and sensitive females (SF, n = 9). Results are shown using box-
plots with medians (lines inside boxes), 25th and 75th percentiles (limits of boxes), and the 10th and 90th percentiles (whiskers). (▼) indicates an
outlier. RELB values are given as arbitrary units after normalization with b-actin. Representative images of Western blots are shown under the
graphs.
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Page 11 of 15condensation could underlie this transcriptional repres-
sion. We used immunofluorescence in situ labeling of
a repressive chromatin state to evaluate the global levels
of DNA and histone methylation in the sample CLLs
(Figure 3). Immunofluorescence staining with HP1a,
3metH3K9 and 5metC showed differences in the distribu-
tion of inactive chromatin markers between resistant and
sensitive cells and is indicative of a global repressive state
of chromatin in the resistant male CLL subset. Indeed,
HP1a, 3metH3K9 and 5metC are associated with hetero-
chromatin-driven transcriptional repression [16].
These observations are in agreement with recently
described features of CLL that involve altered epigenetic
control i.e. the over-expression of nucleolin and its cyto-
plasmic retention in CLL cells [26] and an altered telo-
mere length in a subset of CLL with a poor prognosis
[27]. Indeed, the nucleolar structure involving nucleolin
and telomere lengths has been shown to be controlled
by epigenetic factors, such as H3K9 methylation [28,29].
RELB was elucidated as one of three discriminatory
genes since its relative expression, reflected by the ratio
R/S, was opposite between male and female CLL. The
level of histone H3K9 trimethylation significantly
increased in three promoter regions of RELB,t w oo f
them contain potential DNA-binding sites for the
STAT3 and PAX5 (Figure 1, see also additional file
Table S2) transcriptional factors that may be blocked by
this type of histone modification. Of note, this region
contains the motifs for 20 TFs which may be potentially
involved in the RELB transcriptional control. The obser-
vation that the level of acetyl-H3, used as the marker of
positive gene expression, was extremely low in male
samples while in resistant female samples it was signifi-
cantly high (Figure 2), further highlighted the role
of epigenetic differences between male and female
CLL samples. Hence, in the same promoter regions,
histone modifications were not found to be associated
with DNA methylation (Figure 7). Effectively, DNA
Figure 7 DNA methylation analysis of the RELB promoter region. The sequence shown extends from the -259 bp region of the promoter
to the +169 bp position in exon 1. R, resistant; S, sensitive; M, male; F, female. White spot, no methylation; black spot, methylation.
Figure 8 Down-regulation of RelB expression by HDAC
inhibitor TSA. Primary B cells from healthy donor (CD19
+), cells
from male or female CLL patients (CLLM and CLLF, respectively), or
Ramos B cell line (established from Burkitt lymphoma’s patient),
used as control, were untreated (NT) or preincubated for 16 hr with
200 nM trichostatin A (TSA). Total protein fraction was prepared as
described in Methods section. Western blot analyses show that TSA
induced RelB down-regulation in all B cell types tested.
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Page 12 of 15methylation was investigated in regions that were more
proximal from TSS and first exon than those investi-
gated for 3metH3K9. According to UCSC Genome
Browser http://genome.ucsc.edu on Human Mar. 2006
(NCBI36/hg18), the assembly used for this study, RELB
gene position was 50,196,552 - 50,233,292 and mRNA at
50,196,535. The most proximal CpG islet is located
50,196,420 - 50,197,139. This means that the most prob-
able site for DNA methylation is located -115 bp
upstream TSS. The region of the RELB locus that was
bisulfite sequenced was a 428-bp region comprising the
promoter (from -259 bp) and first exon (to +169 bp).
Thus, we probably cover the region that is the most
likely affected by DNA methylation.
DNA methylation could be correlated (but not neces-
sarily) with histone H3K9 modifications and vice versa.
This discrepancy may be due to the fact that histone
methylation is not always overlapping with CpG islands
regions. The fact that we investigate upstream sequences
for histone modifications might lead to under-estimate a
putative 3metH3K9 modification in the sequences inves-
tigated for DNA methylation, and this results that RELB
could be even more silenced than we proposed. There-
fore, our findings support that H3K9 methylation rather
than deoxycytosine methylation is responsible for RELB
silencing.
As learned from the expression regulation of some
autosomal genes, genes that are specifically maternally
repressed may be CpG-hypomethylated to the same
extent as paternally over-expressed genes. This suggests
that DNA methylation is not necessarily modified in the
transcriptionally “open” nucleosomal state at the promo-
ter region [30]. In addition, an impairment of DNA and
histone modifications has been observed in a mouse leu-
kemia cell line, L1210, where an inverse relationship in
the regulation of the silencing of candidate genes was
reported [31]. This suggests that the methylation of
DNA and histones is less cooperative in hematological
cancers compared with other types of malignant cells.
We recently reported that an epigenetic heterochromati-
nisation may be the mechanism involved in telomere
shortening in both female- and male-derived resistant
CLL cells [32,33] resulting in an aberrant chromatin
structure of telomeric regions. Together with current
data, it appears evident that there is an altered epige-
netic control involved in heterochromatinisation in CLL
cells. While B cell lineage differentiation have been
shown to depend on inherited epigenetic factors it could
be speculated that malignant transformation of CLL
cells results from an epigenetic defect resulting in a
modified expression of RELB which is potentially
involved in this process. Whether RELB inactivation in
males occurs concomitantly with malignant B cell trans-
formation, warrants further investigations.
The NF-B family is a tightly coordinated group of five
identified transcription factors with structural homologies
enabling them to be involved in two major cellular
responses mainly related to stress and inflammation as
well as to cancer development and progression [34]. With
regards to the aggressiveness of CLL, the RelA member of
the NF-B family, involved in its heterodimeric form with
p50 and through its temporal transactivation of “regulon”
type genes in a canonical manner, has been recently
reported to be associated with both in vitro survival and
clinical disease progression in CLL. NF-B pathway activa-
tion is achievable exogenously by stress (reactive oxygen
species or DNA damage) or by death receptor stimulation.
While this activation might results in a pro- or anti-
apoptotic signaling we could speculate that the success of
therapy would depend on its activity. In consequence, this
finding suggests that RELB is a promising new therapeutic
target for this disease [35]. Moreover, as an NF-B family
member associated with the control of the adaptive
immune response and the response to metabolic stress,
RelB may be of particular interest in the emergence
of progressive form of CLL since the alternative NF-B
pathway is potentially involved in both early and late dif-
ferentiation of B cells [36,37]. Together with our demon-
strations of local heterochromatinization of telomeric
regions [32,33] and in agreement with the recently discov-
ered role for the multifunctional transcriptional positive
coactivator 4 (PC4) in targeting heterochromatinization in
non-neuronal human cells [38], different levels of RelB
expression between female and male CLL cells may
involve a cell differentiation- and/or gender-specific factor
that controls a dynamic state of chromatin region contain-
ing RELB.
Conclusion
We have used a microarray approach to analyze the gene
expression profiles of a restricted number of CLL sam-
ples segregated according to the patient gender and to
the cell sensitivity to undergo or not DNA damage-
induced apoptosis in vitro. This experimental plan
allowed us to identify RELB as the new gene epigeneti-
cally down-regulated in a sex-dependent manner in cells
resistant to apoptosis. This was subsequently confirmed
and validated in a larger cohort of CLL samples. Whereas
the incidence of CLL is also sex-dependent, the origin of
CLL cell remains still unknown and the disease remains
still incurable, these findings should initiate a develop-
ment of new approaches targeting RelB and alternative
NF-B pathway that might be discriminative between
CLL leukemogenesis in males and females.
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